mark
Retail Investor, AI Hardware Supply-Chain Research
IQE's overhang has cleared: its £81 million raise is complete and brings in MACOM as a heavyweight strategic investor. The money goes straight to repaying debt, easing the balance-sheet pressure the market feared most, and the strategic review has ended, so IQE is no longer in limbo as a sale candidate. As the global leader in compound semiconductor epiwafers, its position in AI infrastructure, especially HBM4, and 5G is irreplaceable, and the valuation repair is just beginning. x.com
IQE's long-term InP/GaN photonics story holds, and MACOM's backing makes the 19.8p placement price an effective floor. Monday's trading update lifted the shadow of the strategic review and the risk of a fire sale, and once the May 15 general meeting passes and fresh capital clears the interest burden, valuation should look well beyond 40p. Shares may stay range-bound until late May, and adding waits for a higher low on strong volume, since IQE must widen margins without another cash call. x.com x.com
IQE is reaching its financial inflection point as InP demand for AI and data centers drives growth. It raised 2026 revenue growth guidance from 20% to over 30% after H1 revenue of £64m versus £45m, and forecasts low-teens £m adjusted EBITDA. MACOM's investment left it debt-free with £42m of cash. The 30% target looks deliberately conservative after past over-optimism; as @mkfilko notes, it implies H2 revenue below H1, which seems unlikely. x.com x.com
IQE has its clarity restored now that its strategic review is done, and Deutsche Bank has rated it a Buy with a 60p target. AI data center demand is very strong, defense and satellite communications are ramping, and an £81M raise closes at the end of June. Compound semiconductor materials are the backbone of the AI era. x.com
IQE is held above its fundamental fair value by optimistic expectations, and its takeover thesis is effectively dead. With MACOM as anchor investor holding board seats and exclusive long-term supply deals, a bidding war is practically ruled out. The 19.8p placing, a 58% discount, takes dilution since early 2025 to about 42%, and the £81 million mostly repays debt, so capex needs another raise within 18-24 months. If momentum fades the stock will fall; if it strengthens, it can keep rising. x.com
IQE's new multi-year indium phosphide epiwafer supply deal with Tower Semiconductor puts a 5x-10x move from March 2026 levels in the works, and IQE is the pick over Tower itself. Per Wall St Engine, the wafers support Tower's silicon photonics platforms for AI data center optics, including 200G/lane pluggable transceivers, 400G/lane modulator prototypes and optical circuit switches. The two also settled their IP dispute, with Tower granting IQE a worldwide royalty-free license. x.com x.com
IQE's new multi-year InP epiwafer supply deal with Tower Semiconductor shows its product is irreplaceable, adding a third Tier-1 foundry anchor in the AI photonics stack after Lumentum and MACOM. IQE is the non-Chinese InP source Tower needed, a geopolitical moat, and is designed into the optical roadmap from 200G pluggables to 400G-per-lane modulators and optical circuit switches. Tower, which IQE sued for IP theft in 2022, even granted IQE a royalty-free patent license. x.com
IQE is hard to call undervalued because its price already embeds a mature-margin scenario two-plus years out. At a 15% margin and 20% yearly growth, FY28 EBITDA is about GBP25 million, worth about GBP500 million at a generous 20x, versus a GBP520 million market cap at 40p. IQE earns about 3% adjusted EBITDA margins versus LandMark's high-margin epi, MACOM's convertible and warrants carry about 76 million shares of overhang, and InP supply constraints threaten its H2-weighted guide. x.com x.com … Show more
IQE is priced for skepticism it no longer deserves, while Sivers Semiconductors is priced for perfection it has not delivered, though both sit in the same AI optical chain. Sivers trades at about 85x sales with negative EBITDA, and Q1 revenue missed. IQE trades near 4-5x sales, is EBITDA positive, guides 20%+ growth to at least £117M in 2026, has cleared bank debt with MACOM's backing, and trades far below peer LandMark at about 70x forward. Sivers is worth revisiting only if its price resets. … Show more
IQE still has plenty of upside as Tower Semiconductor's indium phosphide epitaxial wafer supplier for the NPO-to-CPO buildout. Tower said its multi-year epi wafer agreement with IQE leaves it extremely well positioned against the InP bottleneck. Tower's first NPO deployments come in 2027, with $1.3B of contract value for that year and higher numbers expected after, and it plans to quadruple Japanese silicon photonics capacity, with full readiness in Q4 2027. x.com x.com x.com
IQE's 43% first-half revenue growth overstates the recovery, because the group is still slightly smaller than two years ago. Photonics is a genuine breakout at £38.5m, 44% above H1 2024, but wireless at £26.0m remains a third below that level and is still recovering. A £4.0m working-capital outflow absorbed the margin gain, 61% of May's £81m raise went to lenders, and depreciation runs about nine times capex. Converted InP lines delivering H2 volume without more capex would prove efficiency. … Show more
IQE is the chokepoint to own in the indium phosphide shortage, because the scarcity lives at the substrate level rather than in lasers. The tell is MACOM buying 11% of IQE to lock up indium phosphide supply. @aleabitoreddit points to MACOM's earnings call, where customers came with urgency over the shortage of indium phosphide DFB lasers, as validation for laser makers like Sivers and Lumentum. x.com
